Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus: A Gynecologic Oncology Group study

R. Asbury, J. A. Blessing, D. M. Smith, L. F. Carson

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Aminothiadiazole was used to treat 21 patients with metastatic or recurrent leiomyosarcoma of the uterus. All patients received a starting dose of aminothiadiazole of 125 mg/m2 intravenously (30- to 45-minute infusion), which was repeated at weekly intervals. All patients also took allopurinol 300 mg per day orally to prevent hyperuricemia, a side effect of aminothiadiazole. Five patients (25%) had stable disease but there were no objective responses. Toxicity was generally mild with this regimen. There was no life-threatening toxicity and only three episodes of severe toxicity. One patient experienced both grade 3 leukopenia and thrombocytopenia, while another patient had grade 3 nausea and vomiting. Further studies in this disease are not planned.

Original languageEnglish (US)
Pages (from-to)397-399
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume18
Issue number5
DOIs
StatePublished - 1995

Keywords

  • Aminothiadiazole
  • Leiomyosarcoma of the uterus

Fingerprint Dive into the research topics of 'Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.

Cite this